GLP-1 weight-loss drugs
Hormone-mimicking injections and pills cut body weight by 15 to 20 percent and help the heart and kidneys.
Open in the interactive tree →GLP-1 is a gut hormone that raises insulin and reduces appetite. Semaglutide (Wegovy) won US approval for obesity in 2021, and tirzepatide, which also targets a second hormone, followed in 2023. Trials show average weight loss of about 15 percent (semaglutide) to about 20 percent (tirzepatide), plus benefits for heart disease and diabetes.
As of October 2026
On 1 April 2026 the FDA approved orforglipron (Foundayo), the first once-daily GLP-1 pill without food or water restrictions, 50 days after filing under a priority voucher program; in the ATTAIN-1 trial the top dose gave 11.2 percent weight loss after 72 weeks versus 2.1 percent with placebo (12.4 percent for those who stayed on treatment). An oral version of Wegovy was approved in December 2025. The phase 3 TRIUMPH-1 trial of retatrutide, a triple-hormone drug, was first reported by Lilly in May 2026 and published in NEJM on 29 September 2026: 25.0 percent weight loss at the top dose after 80 weeks versus 3.9 percent with placebo (2,339 adults); it is still an investigational drug. Semaglutide patents expired in Canada and India in 2026, and generic versions have launched there.
Open steps
- Losing fat but keeping muscle Medium AI leverageWeight-loss drugs also remove muscle; add-on drugs and programmes that keep strength and function, especially in older patients, must be proven.
- Safety over decades Medium AI leverageRare harms such as optic nerve damage appear only at scale; years of follow-up in millions of users are needed to find and weigh them.
- Cheap oral drugs for obesity Medium AI leveragePeptide injections are costly to make; small-molecule pills are easier to scale, and AI-designed next versions could add potency and lower cost.
- Keeping weight off after stopping Medium AI leverageMost weight returns after stopping; lower maintenance doses, patient selection and ways to leave therapy must be tested in long trials.
Where AI could help
Low AI leverage. What remains is supply, price, long-term safety and access, which AI barely touches; it mainly helps design next-generation peptides.
- De novo design of longer-acting or oral peptides
- Mining health records for rare side effects and for who responds
- Process modeling for peptide manufacturing
- Finding non-GLP-1 targets for patients who do not respond
Shown so far
- In March 2025 a Shanghai Jiao Tong preprint reported 10,000 AI-designed GLP-1 receptor agonists, of which two had about three times semaglutide's half-life in animal tests (preprint, no human data). source
Prerequisites
- Periodic Table of Elements1869
- Hormones1902-1905GLP-1 drugs copy a gut hormone that signals fullness and raises insulin
- Insulin1921Peptide-hormone therapy for diabetes began with insulin
- Genetic engineering1973
- Statins and heart prevention1987Like statins, GLP-1 drugs are valued for lowering heart attack and stroke risk